Neuraminidase, putative (Streptococcus pneumoniae) (SP1326)

Neuraminidase – putative (specifically SP1326 in Streptococcus pneumoniae) is a glycosyl hydrolase enzyme that serves as a critical virulence factor in the pathogenesis of invasive pneumococcal disease (IPD). It is encoded within the pathogenicity island known as Region of Diversity 8a (RD8a) and is highly correlated with the bacterium's ability to transition from asymptomatic colonization to severe invasive infections such as pneumonia, sepsis, and meningitis. The enzyme functions by cleaving terminal sialic acid residues from host cell surface glycoconjugates, which facilitates bacterial adhesion, biofilm formation, and the exposure of underlying receptors for further invasion. As a key determinant of pathogenicity, SP1326 is considered a promising therapeutic target for the development of novel antibacterials and vaccines. While traditional neuraminidase inhibitors like oseltamivir and zanamivir are primarily used to treat influenza by targeting viral neuraminidases, research is ongoing to develop small-molecule inhibitors specifically optimized for bacterial sialidases. Targeting this enzyme aims to prevent the initial stages of infection and reduce the severity of invasive disease caused by multidrug-resistant pneumococcal strains.

Other names

SP1326Putative neuraminidaseSialidaseExo-alpha-sialidase

Inhibition of sialic acid cleavage from host cell surface glycoconjugates, thereby preventing bacterial attachment, colonization, and subsequent tissue invasion.